Genomtec (GMT) Q4 2024 earnings summary

Executive summary

• Focus on R&D in biotechnology, with flagship Genomtec ID and OncoSNAAT projects advancing toward commercialization; no significant sales revenue yet, with operations funded by equity and grants.

• 2024 marked by clinical trials, patent grants, and organizational restructuring to enable potential M&A and technology spin-offs.

• Two major equity raises: PLN 10.67m in April 2024 (series O) and PLN 10.8m in March 2025 (series P), plus ongoing grant funding for R&D.

Financial highlights

• Revenue from sales remained minimal at PLN 1k, unchanged year-over-year; main income from grants (PLN 2,320k, up 103%).

• Net loss deepened to PLN -11,208k from PLN -9,013k year-over-year, driven by high R&D and SG&A costs.

• Cash and equivalents at year-end: PLN 6,697k (up from PLN 4,169k); total assets: PLN 17,041k.

• Equity: PLN 7,600k (down from PLN 8,302k); short-term liabilities: PLN 5,481k; long-term: PLN 3,960k.

• No dividend paid; accumulated losses to be covered by future profits.

Outlook and guidance

• Sufficient liquidity for at least 12 months, supported by recent equity and grant inflows.

• Commercialization of Genomtec ID and OncoSNAAT targeted via licensing, sale, or strategic partnership; M&A process ongoing.

• Further equity raises possible if commercialization is delayed.